Literature DB >> 17803231

An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.

Sílvia Atrian1, Eduardo López-Viñas, Paulino Gómez-Puertas, Amparo Chabás, Lluïsa Vilageliu, Daniel Grinberg.   

Abstract

Gaucher disease, the most prevalent lysosomal storage disorder, is principally caused by malfunction of the lysosomal enzyme glucocerebrosidase (GBA), a 497-amino acid membrane glycoprotein that catalyzes the hydrolysis of glucosylceramide to ceramide and glucose in the presence of an essential 84-residue activator peptide named saposin C (SapC). Knowledge of the GBA structure, a typical (beta/alpha)(8) TIM barrel, explains the effect of few mutations, directly affecting or located near the catalytic site. To identify new regions crucial for proper GBA functionality, we analyzed the interactions of the enzyme with a second (substrate) and a third (cofactor) partner. We build 3D docking models of the GBA-SapC and the GBA-ceramide interactions, by means of methodologies that integrate both evolutive and structural information. The GBA-SapC docking model confirm the implication of three spatially closed regions of the GBA surface (TIM barrel-helix 6 and helix 7, and the Ig-like domain) in binding the SapC molecule. This model provides new basis to understand the pathogenicity of several mutations, such as the prevalent Leu444Pro, and the additive effect of Glu326Lys in the double mutant Glu326Lys-Leu444Pro. Overall, 39 positions in which amino acid changes are known to cause Gaucher disease were localized in the GBA regions identified in this work. Our model is discussed in relation to the phenotype (pathogenic effect) of these mutations, as well as to the enzymatic activity of the recombinant proteins when available. Both data fully correlates with the proposed model, which will provide a new tool to better understand Gaucher disease and to design new therapy strategies. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17803231     DOI: 10.1002/prot.21554

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  15 in total

1.  Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S.

Authors:  Marc N Offman; Marcin Krol; Israel Silman; Joel L Sussman; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

Review 2.  GBA-Associated Parkinson's Disease and Other Synucleinopathies.

Authors:  Ziv Gan-Or; Christopher Liong; Roy N Alcalay
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-08       Impact factor: 5.081

3.  Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning.

Authors:  Raquel Romero; Arvind Ramanathan; Tony Yuen; Debsindhu Bhowmik; Mehr Mathew; Lubna Bashir Munshi; Seher Javaid; Madison Bloch; Daria Lizneva; Alina Rahimova; Ayesha Khan; Charit Taneja; Se-Min Kim; Li Sun; Maria I New; Shozeb Haider; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-26       Impact factor: 11.205

4.  Saposin C protects glucocerebrosidase against α-synuclein inhibition.

Authors:  Thai Leong Yap; James M Gruschus; Arash Velayati; Ellen Sidransky; Jennifer C Lee
Journal:  Biochemistry       Date:  2013-10-01       Impact factor: 3.162

5.  Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy.

Authors:  Thai Leong Yap; Zhiping Jiang; Frank Heinrich; James M Gruschus; Candace M Pfefferkorn; Marilia Barros; Joseph E Curtis; Ellen Sidransky; Jennifer C Lee
Journal:  J Biol Chem       Date:  2014-11-26       Impact factor: 5.157

Review 6.  The role of saposin C in Gaucher disease.

Authors:  Rafael J Tamargo; Arash Velayati; Ehud Goldin; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2012-05-05       Impact factor: 4.797

7.  Skin barrier lipid enzyme activity in Netherton patients is associated with protease activity and ceramide abnormalities.

Authors:  Jeroen van Smeden; Hanin Al-Khakany; Yichen Wang; Dani Visscher; Nicole Stephens; Samira Absalah; Herman S Overkleeft; Johannes M F G Aerts; Alain Hovnanian; Joke A Bouwstra
Journal:  J Lipid Res       Date:  2020-04-07       Impact factor: 5.922

Review 8.  Molecular regulations and therapeutic targets of Gaucher disease.

Authors:  Yuehong Chen; Neetu Sud; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-11       Impact factor: 7.638

9.  Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2.

Authors:  Friederike Zunke; Lisa Andresen; Sophia Wesseler; Johann Groth; Philipp Arnold; Michelle Rothaug; Joseph R Mazzulli; Dimitri Krainc; Judith Blanz; Paul Saftig; Michael Schwake
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-21       Impact factor: 11.205

10.  Novel pathogenic mutations in the glucocerebrosidase locus.

Authors:  Raquel Duran; Alisdair McNeill; Atul Mehta; Derralyn Hughes; Timothy Cox; Patrick Deegan; Anthony H V Schapira; John Hardy
Journal:  Mol Genet Metab       Date:  2012-05-18       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.